NBY vs. NRSN, FLGC, TRAW, EDSA, RDHL, AKTX, IMNN, PIRS, KPRX, and ELAB
Should you be buying NovaBay Pharmaceuticals stock or one of its competitors? The main competitors of NovaBay Pharmaceuticals include NeuroSense Therapeutics (NRSN), Flora Growth (FLGC), Traws Pharma (TRAW), Edesa Biotech (EDSA), RedHill Biopharma (RDHL), Akari Therapeutics (AKTX), Imunon (IMNN), Pieris Pharmaceuticals (PIRS), Kiora Pharmaceuticals (KPRX), and Elevai Labs (ELAB). These companies are all part of the "pharmaceutical preparations" industry.
NeuroSense Therapeutics (NASDAQ:NRSN) and NovaBay Pharmaceuticals (NYSE:NBY) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, dividends, media sentiment, analyst recommendations, risk and community ranking.
NeuroSense Therapeutics has a net margin of 0.00% compared to NeuroSense Therapeutics' net margin of -80.76%. NeuroSense Therapeutics' return on equity of -304.39% beat NovaBay Pharmaceuticals' return on equity.
NeuroSense Therapeutics received 2 more outperform votes than NovaBay Pharmaceuticals when rated by MarketBeat users. Likewise, 100.00% of users gave NeuroSense Therapeutics an outperform vote while only 0.00% of users gave NovaBay Pharmaceuticals an outperform vote.
NovaBay Pharmaceuticals has higher revenue and earnings than NeuroSense Therapeutics. NeuroSense Therapeutics is trading at a lower price-to-earnings ratio than NovaBay Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
NeuroSense Therapeutics has a beta of 1.73, indicating that its stock price is 73% more volatile than the S&P 500. Comparatively, NovaBay Pharmaceuticals has a beta of 2.03, indicating that its stock price is 103% more volatile than the S&P 500.
In the previous week, NovaBay Pharmaceuticals had 1 more articles in the media than NeuroSense Therapeutics. MarketBeat recorded 4 mentions for NovaBay Pharmaceuticals and 3 mentions for NeuroSense Therapeutics. NovaBay Pharmaceuticals' average media sentiment score of 0.62 beat NeuroSense Therapeutics' score of -0.75 indicating that NeuroSense Therapeutics is being referred to more favorably in the media.
1.0% of NeuroSense Therapeutics shares are held by institutional investors. Comparatively, 23.3% of NovaBay Pharmaceuticals shares are held by institutional investors. 27.4% of NeuroSense Therapeutics shares are held by company insiders. Comparatively, 0.1% of NovaBay Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Summary
NovaBay Pharmaceuticals beats NeuroSense Therapeutics on 8 of the 15 factors compared between the two stocks.
Get NovaBay Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for NBY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NBY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NovaBay Pharmaceuticals Competitors List
Related Companies and Tools
